Nebula Research & Development LLC Catalyst Pharmaceuticals, Inc. Transaction History
Nebula Research & Development LLC
- $464 Billion
- Q1 2024
A detailed history of Nebula Research & Development LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 10,703 shares of CPRX stock, worth $165,789. This represents 0.04% of its overall portfolio holdings.
Number of Shares
10,703Holding current value
$165,789% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
277Shares Held
95.7MCall Options Held
40.6KPut Options Held
67.2K-
Black Rock Inc. New York, NY17.7MShares$275 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$141 Million3.01% of portfolio
-
State Street Corp Boston, MA8.15MShares$126 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.98MShares$124 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.74MShares$42.4 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $1.59B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...